Repeatability and Reproducibility of Multiparametric MRI
NCT ID: NCT03743272
Last Updated: 2025-12-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
61 participants
OBSERVATIONAL
2017-06-03
2024-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Repeatability and Reproducibility of Quantitative MRCP
NCT03809559
Patient Understanding of LiverMultiScan
NCT02877602
Non-invasive Rapid Assessment of NAFLD Using Magnetic Resonance Imaging With LiverMultiScan
NCT03289897
Fully Automated High-Throughput Quantitative MRI of the Liver
NCT05294471
Multi-Parametric MRI Assessment of the Liver in the Dallas-FortWorth Metroplex Population
NCT04336618
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Magnetic resonance (MR) techniques offer an attractive non-invasive option for liver assessment. Multiparametric MRI is a safe and non-invasive method for quantification of liver tissue characteristics. Images for quantification of hepatic fat from proton density fat fraction (PDFF) maps, T2\*, and iron-corrected T1 (cT1) can be rapidly obtained during abdominal breath-hold acquisitions without the need for contrast agents or additional external hardware. Iron correction of T1 is necessary to address the confounding effects of excess iron, which is common in chronic liver disease. LiverMultiScan™ (LMS, Perspectum Diagnostics, Oxford, UK) is a software application that can be used with supported MR-systems to correct T1 for the effects of excess iron, and thus, to calculate cT1 from T1 and T2\* maps, and standardise to a 3T field strength.
This method has been shown to have high diagnostic accuracy for the assessment of liver fibrosis compared to histology, predict clinical outcomes in patients with mixed liver disease aetiology, stratify patients with non-alcoholic steatohepatitis (NASH) and cirrhosis, reliably exclude clinically significant liver disease and is cost-effective in diagnosing NAFLD.
In addition to demonstrating accuracy, imaging biomarker validation requires precision and repeatability (US Department of Health and Human Services, 2015). From a clinical perspective, it is essential to ensure that there is good inter-examination repeatability, so that any changes seen can be correctly attributed to disease progression or regression, rather than inter-examination variability. This is tested by examining the closeness of repeated measurements made in different MR examinations (with both subject and coil repositioning) over a time frame in which physiologic conditions are assumed constant.
This study aims to systematically test the repeatability and reproducibility of each multiparametric MRI measurement, cT1, T2\* and PDFF, corresponding to hepatic fibro-inflammation, iron and fat respectively, across scanner field strength, manufacturer and model in human participants and phantoms.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Liver condition
Participants who have a history of of liver disease
LiverMultiScan
Up to 6 separate 5-10 minute abdominal MRI scans. Each scan requires a short breath hold.
Healthy volunteers
Participants who have do not have a diagnosed liver condition and are in general good health
LiverMultiScan
Up to 6 separate 5-10 minute abdominal MRI scans. Each scan requires a short breath hold.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
LiverMultiScan
Up to 6 separate 5-10 minute abdominal MRI scans. Each scan requires a short breath hold.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participant is willing and able to give informed consent.
Exclusion Criteria
* Any other cause, including a significant disease or disorder which, in the opinion of the investigator, may either put the participant at risk because of participation in the study or affect the participant's ability to participate in the study.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Perspectum
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rajarshi Banerjee, BM BCh MS DPhil
Role: PRINCIPAL_INVESTIGATOR
Perspectum Diagnostics
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Leiden University Medical Centre
Leiden, , Netherlands
Addenbrookes Hospital
Cambridge, Cambridgeshire, United Kingdom
University of Oxford Centre for Clinical Magnetic Resonance Research (OCMR)
Oxford, Oxfordshire, United Kingdom
Southampton General Hospital
Southampton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Pickles E, Kumar S, Brady M, Telford A, Pavlides M, Bulte D. Comparison of liver iron concentration calculated from R2* at 1.5 T and 3 T. Abdom Radiol (NY). 2023 Mar;48(3):865-873. doi: 10.1007/s00261-022-03762-4. Epub 2022 Dec 15.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LMSRR
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.